Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
11/2010
11/11/2010US20100285058 Dna vaccine for treating or preventing cervical cancer comprising a gene encoding hpv protein
11/11/2010US20100285056 Baculovirus-Based Vaccines
11/11/2010US20100285055 Activation of natural killer (NK) cells and methods of use
11/11/2010US20100285046 Nontoxic ricin mutant compositions and methods
11/11/2010US20100285044 Method and compositions for treatment of cancers
11/11/2010US20100285041 Class A Oligonucleotides with Immunostimulatory Potency
11/11/2010US20100285039 B7-H1 (CD274) Antagonists Induce Apoptosis of Tumor Cells
11/11/2010US20100285038 Factor Involved in Metastasis and Uses Thereof
11/11/2010US20100285037 Antibodies to cll-1
11/11/2010US20100285036 Anti-CD100 Neutralizing Antibodies and Methods of Using the Same
11/11/2010US20100285035 High Affinity Antibody Antagonists of Interleukin-13 Receptor Alpha 1
11/11/2010US20100285034 Method
11/11/2010US20100285031 Hox Compositions and Methods
11/11/2010US20100285030 Antibodies to Ox-2/Cd200 and Uses Thereof
11/11/2010US20100285026 Phosphorylation of histone h3 at threonine 11 - a novel epigenetic mark for transcriptional regulation
11/11/2010US20100285025 Antibodies specific for the c-terminal regulatory domain of egfr and their use
11/11/2010US20100285023 Detecting cyp24 expression level as a marker for predisposition to cancer
11/11/2010US20100285020 Leukemic cell cns infiltration controlled by notch-induced chemotaxis
11/11/2010US20100285018 Estrogen receptors and methods of use
11/11/2010US20100285017 Matriptase protein and uses thereof
11/11/2010US20100285014 Immunoglobulin fusion proteins
11/11/2010US20100285013 Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof
11/11/2010US20100285012 Methods and compositions for the treatment of cancers and pathogenic infections
11/11/2010US20100285010 Tumor therapy with an anti-vegf antibody
11/11/2010US20100285009 Humanized anti-egfl7 antibodies and methods using same
11/11/2010US20100285008 Benzoquinone derivative e3330 in combination with chemotherapeutic agents for the treatment of cancer and angiogenesis
11/11/2010US20100285007 Differential diagnosis of b-cell chronic lymphocytic leukemia
11/11/2010US20100285006 Compositions of Kinase Inhibitors and Their Use for Treatment of Cancer and Other Diseases Related to Kinases
11/11/2010US20100285004 Anti-CD38 human antibodies and uses thereof
11/11/2010US20100285003 Therapeutic peptides and uses thereof
11/11/2010US20100285001 Method and Compositions Related to Synergistic Responses to Oncogenic Mutations
11/11/2010US20100284992 Phospholipase C and Method of Use
11/11/2010US20100284989 15-pgdh in colon cancer
11/11/2010US20100284982 Erythrocyte-encapsulated L-asparaginase for enhanced acute lymphoblastic leukemia therapy
11/11/2010US20100284975 Polypeptides comprising fas activation and nkg2d-ligand domains
11/11/2010US20100284965 Compositions and methods for adoptive and active immunotherapy
11/11/2010US20100284964 Cancer therapy
11/11/2010US20100284962 Modified tumor necrosis factor-beta
11/11/2010US20100284938 Penetrating pharmaceutical foam
11/11/2010US20100284935 Markers and diagnostic methods for metastasis
11/11/2010US20100284924 Nano-devices having impellers for capture and release of molecules
11/11/2010US20100284921 Targeted nanoparticles for intracellular cancer therapy
11/11/2010US20100284918 Protein
11/11/2010US20100284915 Genes associated with chemotherapy response and uses thereof
11/11/2010US20100284912 Homogenization of a radiopharmaceutical using sonification and/or rotor-stator technology to produce a homogenous suspension, emulsion, mixture or solid suspension of immiscible ingredients
11/11/2010US20100284911 Preparations and methods for treating malignancies
11/11/2010US20100284910 Novel Method of Diagnosing, Monitoring, Staging, Imaging and Treating Various Cancers
11/11/2010US20100284909 Immunotherapy targeting of the shared abnormal conformational state of amyloidogenic peptides/proteins
11/11/2010US20100284908 Proteins
11/11/2010US20100284907 Treatment of tumors by ablating bone marrow-derived endothelial progenitor cells
11/11/2010US20100284906 Internalizing Anti-CD74 Antibodies and Methods of Use
11/11/2010US20100284905 Methods and Agents for Inhibiting Tumor Growth by Targeting the SSDNA Replication Intermediate of Tumor Stem Cells
11/11/2010DE102009019962A1 3-([1,2,3]Triazol-4-yl)-pyrrolo[2,3-b]pyridinderivate 3 - ([1,2,3] triazol-4-yl) pyrrolo [2,3-b] pyridine
11/11/2010CA2838400A1 Humanized anti-egfl7 antibodies and methods using same
11/11/2010CA2761182A1 Pyrrolidine-substituted flavones as radio-sensitizers for use in the treatment of cancer
11/11/2010CA2761146A1 Antitumor combination including ave8062 and sorafenib
11/11/2010CA2761120A1 Uses of immunoconjugates targeting cd138
11/11/2010CA2761079A1 Antitumor combination including cabazitaxel and capecitabine
11/11/2010CA2760953A1 Triptolide prodrugs
11/11/2010CA2760929A1 Pmk2 modulators for use in the treatment of cancer
11/11/2010CA2760890A1 Anti-cd100 antibodies and methods for using the same
11/11/2010CA2760844A1 3-(1,2,3-triazol-4-yl)pyrrolo[2,3-b]pyridine derivatives
11/11/2010CA2760794A1 Egfr inhibitors and methods of treating disorders
11/11/2010CA2760310A1 Compositions and methods for enhancing antigen-specific immune responses
11/11/2010CA2760061A1 Diamino heterocyclic carboxamide compound
11/11/2010CA2759997A1 Pyrrolo [2, 3. b] pyridines which inhibit raf protein kinase
11/11/2010CA2759078A1 Compositions and methods of use for binding molecules to dickkopf-1 or dickkopf-4 or both
11/11/2010CA2758302A1 Compounds and compositions comprising cdk inhibitors and methods for treatment of cancer
11/10/2010EP2248910A1 Epitope synchronization in antigen presenting cells
11/10/2010EP2248895A2 Combination therapy associating a TGF-beta antagonist with a chemotherapeutic agent
11/10/2010EP2248832A1 A g-csf conjugate modified by water-soluble polymer
11/10/2010EP2248831A1 Glycosylated antibodies
11/10/2010EP2248829A1 Treatment with anti-VEGF antibodies
11/10/2010EP2248807A1 N-phenyl-2-pyrimidine-amine derivatives
11/10/2010EP2248806A2 Quinazoline derivatives as tyrosine kinase inhibitors
11/10/2010EP2248804A1 Combined use of angiogenesis inhibitor and taxane
11/10/2010EP2248796A1 2-methylene-5-substituted methylene cyclopentanone derivatives and use thereof
11/10/2010EP2248537A1 Restoration of cancer-suppressing functions to neoplastic cells through DNA hypomethylation
11/10/2010EP2247725A1 Stat3 epitope peptides
11/10/2010EP2247620A1 Anti-cd79b antibodies and immunoconjugates and methods of use
11/10/2010EP2247596A2 Novel pyrazolo [3, 4 -d] pyrimidine derivatives as anti -cancer agents
11/10/2010EP2247590A1 Pyrazolopyrimidines, a process for their preparation and their use as medicine
11/10/2010EP2247588A2 Fused heterocyclic derivative and use thereof
11/10/2010EP2247585A1 Crystal forms of n-ý2-(diethylamino)ethyl¨-5-ý(5-fluoro-1,2-dihydro-2-oxo-3h-indol-3-ylidene)methyl¨-2,4-dimethyl-1h-pyrrole-3-carboxamide and methods for their preparation
11/10/2010EP2247584A1 Fused pyridines active as inhibitors of c-met
11/10/2010EP2247579A1 Sulphoximine-substituted quinazoline derivatives as immunomodulators, their preparation and use as medicaments
11/10/2010EP2247578A1 Hydroxylated pyrimidyl cyclopentanes as akt protein kinase inhibitors
11/10/2010EP2247563A1 13,13-dimethyl-des-c,d analogs of 1alpha, 25-dihydroxy-19-nor-vitamin d3 compounds and topical composition dosage forms and methods of treating skin conditions thereof
11/10/2010EP2247312A2 Compositions and methods for the treatment of tumor of hematopoietic origin
11/10/2010EP2247309A2 Tapasin augmentation for enhanced immune response
11/10/2010EP2247308A1 Adjuvant compositions comprising poly-ic and a cationic polymer
11/10/2010EP2247301A1 Use of therapeutic peptides for the treatment and prevention of cancer
11/10/2010EP2247185A2 Tyrosine kinase inhibitors
11/10/2010EP2111403B1 Triazabenzo[e]azulene derivatives for the treatment of tumors
11/10/2010EP2109612B1 5,6,7,8-tetrahydropteridine derivatives as hsp90 inhibitors
11/10/2010EP2018169B1 Use of 4,17 beta-dihydroxyandrost-4-ene-3-one for treating cancers
11/10/2010EP1995249B1 Camptothecin derivatives and their use
11/10/2010EP1940407B1 N-(4-oxo-3,4-dihydroquinazolin-2-yl)butanamides as androgen receptor modulators
11/10/2010EP1833840B9 Potent lna oligonucleotides for the inhibition of hif-1a
11/10/2010EP1799227B1 Therapeutic agents targeting the nc ca-atp channel and methods of use thereof
1 ... 613 614 615 616 617 618 619 620 621 622 623 624 625 626 627 628 629 630 631 632 633 ... 2211